Objectives: Cytotoxic chemotherapy is an effective and traditional treatment of ovarian cancer. However, chemotherapy-induced apoptosis may also trigger and ultimately accelerate the repopulation of the small number of adjacent surviving cells. This study mainly focused on the tumour cell repopulation caused by chemotherapy in ovarian cancer and the adjunctive/synergistic effect of Berberine on the prevention of tumour repopulation.
| INTRODUCTION
Ovarian cancer is the most common cause of death from gynaecologic cancer worldwide. [1] [2] [3] The conventional ovarian cancer treatment strategy involves debulking surgery, in which visible tumour nodules are removed before chemotherapy. Following cytoreductive surgery, ovarian cancer patients undergo platinum-and taxane-based chemotherapy. 4, 5 However, in over 70% of ovarian cancer cases, patients usually recur within 12-to 24 months after initial diagnosis and die of progressively chemotherapy-resistant disease. 6 Considering the high rate of recurrence of ovarian cancer patients, new therapeutic strategies, especially against relapse after chemotherapy, are urgently needed. 7 Most common chemotherapeutics lead to the induction of apoptosis in the targeted cancer cell, including platinum-and taxane-based chemotherapy in ovarian cancer. 8 Although activation of the caspase 3 is a hallmark of apoptosis and usually tightly associated with response to chemotherapy, it also has been suggested a role in tissue regeneration and repopulation by stimulating signal transduction and cell proliferation in neighbouring, non-apoptotic cells. 9 The cleaved caspase 3 can activate cytosolic calcium-independent phospholipase A2 (iPLA2) 10 and consequently trigger the cascade reaction of AA metabolic pathway, leading to abnormal changes of AA and PGE 2 levels in the microenvironment of tumour. And PGE 2 was reported to stimulate cell proliferation and tumour growth. 11,12 PGE 2 treatment was able to increase the phosphorylation of FAK in hepatocellular carcinoma cells, 13 a 125-kDa non-receptor cytoplasmic protein tyrosine kinase, which has been implicated in the regulation of a variety of cellular signalling pathways that control cell proliferation.
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Berberine, an isoquinoline alkaloid, is found in the rhizome; roots and stem bark the Berberis species, such as Hydrastis canadensis (goldenseal), Cortex phellodendri (Huangbai) and Rhizoma coptidis (Huanglian). [16] [17] [18] Berberine exhibits multiple pharmacological activities, including anticancer and antidiabetes mellitus effects. [19] [20] [21] In our previous studies, we found that Berberine suppressed cPLA 2 and COX-2 gene expressions and inhibited AA pathway by elevating the ratio of AA to PGE 2 in hepatocellular carcinoma in vitro and in vivo. 22 Additionally, Berberine was also found to inhibit phosphorylated forms of FAK of SCC-4 and CRC cells. 23, 24 Therefore, we propose to explore whether Berberine overcomes repopulation of ovarian cancer cells due to activation of caspase 3-mediated AA pathway and phosphorylation of FAK after chemotherapy.
In our study, we utilized transwell system for co-cultures of human Berberine may become a promising strategy to prevent the recurrence of ovarian cancer after chemotherapy.
| MATERIALS AND METHODS

| Chemicals and reagents
Human prostaglandin E 2 ELISA Kit and the Human Arachidonic acid ELISA Kit were purchased from R&D Systems (Minneapolis, MN, USA). 
| Cell culture
The human epithelial ovarian cancer cell line SKOV3 was cultured in RPMI 1640 supplemented with 10% FBS, penicillin and streptomycin at 100 U/mL and 100 μg/mL, respectively. Cells were incubated at 37°C in 5% CO 2 -95% air atmosphere.
| Transwell system
The transwell system (Corning, NY, USA) with 4.0-μm pore size semipermeable membrane filter insert was used for preparing the co-culture system. In the bottom chamber, the SKOV3 cells (10 Supernatants from the upper chambers of the transwell system during the incubation period were collected daily (50 μL per day) for the analysis of the AA and PGE 2 levels by ELISA. After 10-day incubation, receptor cells in the semipermeable filter inserts were fixed by methanol for proliferation assays.
| Proliferation assays
Receptor cells in the semipermeable filter inserts of the transwell system were then stained by 0.1% crystal violet for 20 minutes at room temperature. After washing the wells with PBS twice, the cells on upper surface of the membranes were photographed under the microscope. Finally, the cells were solubilized with 1 mL 33% acetic acid per well and quantified by the absorbance at 570 nm.
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SKOV3 cells were seeded in 2 mL of medium at 1000 cells/well in 6-well culture plates and grown overnight. Treatments of 5 μmol/L Berberine (as group Ber), 3.125 ng/mL prostaglandin E 2 (as group PGE 2 ) and their combination (as group Ber + PGE 2 ) were conducted for 7 days. Prostaglandin E 2 was added into relative groups daily.
Afterwards, the cells were fixed by methanol for proliferation assays as previously described.
| Western blot analysis
Receptor cells of the sixth-day incubation within transwelll system and cells with prostaglandin E 2 treatments were collected for pro- 1.5 hour. Bands were visualized by an ECL Western blotting detection system (Tanon 4200). Grey value of the bands in the Western blot was analysed using Quantity One software.
| Measurement of AA and PGE 2 levels
Supernatants collected from the transwell system during the incubation period were thawed, and prostaglandin E 2 (PGE 2 ) and arachidonic acid (AA) levels were analysed using the Human Prostaglandin E 2 ELISA Kit and the Human Arachidonic acid ELISA Kit according to the manufacturer's instructions. The absorbances were read at a wavelength of 450 nm.
| Statistical analysis
All experiments were completed at least three times unless otherwise indicated. All data were expressed as mean ± SD. Statistical significances among groups were analysed by one-way analysis of variance followed by Dunnett's multiple comparison post-test. A value with P < .05 was considered as statistically significant.
| RESULTS
| Berberine reversed the chemotherapy-induced repopulation of ovarian cancer cells
Recurrence is considered as a cause of cancer treatment failure.
Researchers have observed that radiation-induced apoptotic tumour were solubilized with 1 mL of 33% acetic acid and quantified by the absorbance at 570 nm. Results were expressed as the mean ± SD of three independent experiments, *P < .05 compared with control, #P < .05 compared with VP16 group cells could stimulate the repopulation of tumours from a small number of surviving cells. 10 In our study, we established transwell system 
| Berberine blocked the iPLA 2 -AA-COX-2-PGE 2 pathway induced by caspase 3 activation after chemotherapy
Activation of caspase 3 was indicated to render tissue regeneration and repopulation by stimulating signal transduction and cell proliferation in neighbouring non-apoptotic cells. 10 We found that the VP16 We next measured the level of AA and PGE 2 in the supernatant of the transwell system. As shown in Figure 3 , 5 μmol/L Berberine did not cause significant changes in the levels of AA and PGE 2 compared with control, while the VP16 treatment on feeder cells showed a decrease in AA level ( Figure 3A ) and an increase in PGE 2 level ( Figure 3B ) in a time-dependent manner, with significant differences appearing since day 6, and the addition of Berberine partly reversed these changes of AA and PGE 2 production compared with VP16 group, with significant differences appearing since day 9 ( Figure 3A,B) . These results indicated that Berberine reverses the chemotherapy drug-induced caspase 3-iPLA 2 -AA-COX-2-PGE 2 pathway in SKOV-3 cells.
| Berberine inhibited PGE 2 -stimulated repopulation through the inhibition of FAK phosphorylation
As it was shown in Figures 2 and 3 , we found that the VP16 treatment led to the induction of iPLA 2 and COX-2, as well as the following upregulation of PGE 2 level. In order to determine whether PGE 2 is the key molecule for transducing the activation of caspase 3-mediated regeneration signalling to adjacent cells, exogenous PGE 2 was added into the culture media to mimic the abnormal level of PGE 2 caused by VP16 treatment. SKOV-3 cell proliferation was enhanced expectedly after exogenous PGE 2 treatment compared with Control group. More importantly, the addition of Berberine was still capable to reverse exogenous PGE 2 -stimulated cell proliferation ( Figure 4A ,B).
Previous research found that PGE 2 treatment can increase the phosphorylation of FAK. 13 We then investigated the influence of 
| DISCUSSION
Despite the relative high response for cytotoxicity agents in tumour treatment, chemotherapy is nowadays being questioned by a growing incidence of drug resistance and tumour relapse. Clinically, a large number of responders of ovarian cancer relapse within a short period after completing first-line chemotherapy and require further systemic therapy. 26 For decades, researchers have studied the fundamental mechanism of tumour repopulation from different perspectives such as inflammation, angiogenesis. 27 Until recently, "Phoenix Rising" pathway was thrown out 28 and clearly defined the possible cell deathmediated tumour repopulation in melanoma via a caspase 3-mediated mechanism. 29 Consistent with this concept, our study defined that the caspase 3-mediated growth of living tumour cell stimulated by dying cells also happened in ovarian cancer cells treated with chemotherapy drugs. Patients with recurrent ovarian cancer are rarely curable and often have only short-term progression-free survival. 6 Therefore, preventing recurrence and improving quality of life have become key objectives in the treatment and management of patients with ovarian cancer. In our study, we first investigated the efficacy of Berberine, a natural product with lower cytotoxicity in normal human cells, against the repopulation of ovarian cancer cells after chemotherapy. 19, 30 We found that Berberine showed a significant ability against the VP16- Each bar represents the mean ± SD of three independent experiments, n = 3, *P < .05 compared with control; #P < .05 compared with VP16 group; ns, no significant difference F I G U R E 3 The AA and PGE 2 levels in SKOV3 cells treated by Berberine within the transwell system. The supernatants of each group were collected each day from the transwell system during the 10-day incubation, A, AA and B, PGE 2 levels were measured by ELISA. Three independent experiments were carried out. Results were expressed as the mean ± SD, n = 3, *P < .05 compared with control; #P < .05 compared with VP16 group is an important enzyme in the AA metabolic pathway which converts AA into endoperoxide intermediates that are ultimately converted to prostanoids, including PGE 2 . As a natural product and a COX-2-specific inhibitor, our result showed that Berberine not only maintained the activity of caspase 3, but also retarded the VP16-triggered abnormal PGs production catalysed by COX-2, which is confirmed by the effectiveness of Berberine on inhibiting the expression of COX-2. 36 Given the importance of AA metallic pathway in recurrence of ovarian cancer upon chemotherapy, our result also warranted combined cytotoxic with other therapy targeting AA-COX-2-PGE 2 pathway in the future.
As an accepted key regulator of cellular signalling pathways that These results implied that FAK phosphorylation may be regulated by the level of PGE 2, 37 although the phosphorylation of FAK is traditionally thought to be mediated by integrins. 23 In our study, enhanced phosphorylation of FAK was observed in both VP16 and exogenous PGE 2 treatment condition. More importantly, Berberine was found to abrogate the increasing of phosphorylation of FAK following the inhibition of AA-COX-2-PGE 2 pathway. Further study will be needed to explore whether inhibitory effect of Berberine on the phosphorylation of FAK in ovarian cancer cells due to its direct inhibition on integrin β1, since down regulated the levels of integrin β1 in colorectal carcinoma (CRC) cells was shown with efficacy of Berberine before. 23 In conclusion, Berberine contributed to the inhibition of repopulation of a small number of surviving ovarian cancer cells after the chemotherapy, which was achieved mainly by suppressing the two rate-limiting enzymes iPLA 2 and COX-2 in the dying cells, subsequently reduced the production of PGE 2 in tumour microenvironment.
In the meanwhile, further inhibition of PGE2-FAK in ovarian cancer cells with recurrence potential also played a critical role on tumour relapse. Our work provided a promising strategy on the recurrence prevention of ovarian cancer with the combination of Berberine and caspase 3-activated chemotherapy.
